Methylphenidate improves weight control in childhood brain tumor survivors with hypothalamic obesity

Abstract

Background: Hypothalamic obesity causes unrelenting weight gain for childhood brain tumor survivors. No single therapy has proven effective for treatment. We aimed to evaluate effectiveness of long‐term methylphenidate therapy on body mass index (BMI) change in children with hypothalamic obesity. Methods: A retrospective analysis included children with a history of brain tumor and hypothalamic obesity receiving methylphenidate (10‐60 mg/day) for hypothalamic obesity. Subjects were evaluated for BMI trajectory before and after methylphenidate start. Given that z‐scores can be skewed in severely obese children, we calculated BMI as a percent of the BMI at the 95th percentile for the child's age and gender (BMI% 95th). Results: Twelve patients with hypothalamic obesity completed methylphenidate therapy for at least 6 months (median 3.1 years, range 1.0‐5.8 years). All subjects had a suprasellar tumor (nine [75%] with craniopharyngioma) and pituitary dysfunction. Pretreatment median BMI percent of the 95th percentile was 125.6% (interquartile range [IQR] 25‐75: 115.3‐138.3%) with BMI z‐score of 2.4 (IQR 25‐75: 2.1‐2.6). Following methylphenidate treatment, there was a 69.9% reduction in the median slope of BMI change. Eleven of 12 patients (92%) had a reduction in the slope of their BMI change on methylphenidate treatment. Postmethylphenidate median BMI percent of the 95th percentile decrease to 115.2% (IQR 25‐75: 103.6‐121.2%) with median BMI z‐score of 2.1 (IQR 25‐75: 1.8‐2.2). Mild side effects were noted in six patients. Conclusions: Methylphenidate use reduced and sustained BMI change in children with hypothalamic obesity. Stimulant therapy is an effective first‐line agent for treatment of hypothalamic obesity.